Business
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
1Q26 Total Revenue of ~$71M Delivers ~45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M 40% Confirmed Objective Response Rate in Metastatic Serous Endometrial Cancer SAN CARLOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first
About this update from Iovance Biotherapeutics, Inc.
[{"type":"image","alt":"Iovance Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"Iovance Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":98,"url":"https://media.zenfs.com/en/globenewswire.com/fb47f4fbc477e50ab2663b1d46d1f520"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CpWBAZmzJ.hidpycFVkUTQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNw--/https://media.zenfs.com/en/globenewswire.com/fb47f4fbc477e50ab2663b1d46d1f520","width":300,"height":98},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/CpWBAZmzJ.hidpycFVkUTQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNw--/https://media.zenfs.com/en/globenewswire.com/fb47f4fbc477e50ab2663b1d46d1f520","width":300,"height":98}},"lazy":false},{"type":"text","content":"1Q26 Total Revenue of ~$71M Delivers ~45% Year-over-Year Growth","length":63,"tagName":"p"},{"type":"text","content":"2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M ","length":64,"tagName":"p"},{"type":"text","content":"40% Confirmed Objective Response Rate in Metastatic Serous Endometrial Cancer","length":77,"tagName":"p"},{"type":"text","content":"SAN CARLOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2026 financial results, business achievements, and corporate updates.","length":371,"tagName":"p"},{"type":"text","content":"Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, “We are accelerating the adoption and commercial expansion for Amtagvi after record high demand. Iovance is well positioned through 2026 for long-term revenue growth, while advancing multiple ongoing and new clinical trials, including our registrational trial in advanced sarcomas now underway and encouraging initial data reported today for lifileucel in metastatic serous endometrial cancer. Internal manufacturing efficiencies, operational improvements, and cost reductions will benefit gross margin and propel future profitability, sustainable growth, and long-term value for patients and shareholders.”","length":702,"tagName":"p"},{"type":"text","content":"First Quarter 2026 Financial Highlights Continued S...